The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
Open Access
- 25 July 2022
- journal article
- review article
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 41 (2) , 347-366
Abstract
Systemic treatment options for patients with lung cancer have expanded in recent years, with a number of immunotherapeutic strategies now in our treatment armamentarium. Toxicity of and resistance to treatment hold a major stake in lung cancer morbidity and mortality. Herein, we summarise the background, current evidence and potential mechanisms underlying the role of the commensal gut microbiota in immunotherapy outcomes such as response and toxicity in patients with non-small cell lung cancer (NSCLC).Keywords
This publication has 127 references indexed in Scilit:
- Experimental and analytical tools for studying the human microbiomeNature Reviews Genetics, 2011
- Ipilimumab: its potential in non-small cell lung cancerTherapeutic Advances in Medical Oncology, 2011
- An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaeaThe ISME Journal, 2011
- Has the Microbiota Played a Critical Role in the Evolution of the Adaptive Immune System?Science, 2010
- UniFrac: an effective distance metric for microbial community comparisonThe ISME Journal, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Intestinal Integrity and Akkermansia muciniphila , a Mucin-Degrading Member of the Intestinal Microbiota Present in Infants, Adults, and the ElderlyApplied and Environmental Microbiology, 2007
- An Immunomodulatory Molecule of Symbiotic Bacteria Directs Maturation of the Host Immune SystemCell, 2005
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004